

Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development

- **Professor Karine Lacombe is an international expert in infectious diseases, and brings extensive experience in clinical practice**
- **Catherine George has over 30 years' experience in the pharmaceutical industry in the areas of drug safety and translational medicine**


Paris, France, June 24, 2022

Diaccurate, a French biotechnology company developing “sole-in-class” drug candidates in oncology and immunotherapy, announced today the appointment to its Board of Directors of Professor Karine Lacombe, a renowned expert in infectious diseases, specializing in HIV research and drug development, and Catherine George, President of Ipsen Innovation and Pharm Sciences, specializing in toxicology and translational medicine.

*“I warmly welcome Karine and Catherine to Diaccurate's Board of Directors,” said **Dr. Philippe Pouletty**, Chairman of Diaccurate and co-founder and CEO of Truffle Capital. “Their experience, vision and recommendation will be important to guide the preclinical and clinical development of our programs. The entire Board of Directors is delighted to work with Karine and Catherine to support the Diaccurate team in achieving its goals.”*

*“I am delighted to join Diaccurate's Board of Directors,” said **Professor Karine Lacombe**. “I look forward to working with the talented team at Diaccurate. The Company's programs target very promising areas that hold great hope for the patients. The next steps in development will be crucial to confirm their therapeutic potential.”*

*“I join Diaccurate's Board of Directors with great enthusiasm,” said **Catherine George**. “ The Company's dense and innovative pipeline and the expertise in place puts Diaccurate in a good position to successfully advance clinical programs.”*



DIACURATE

NEWS RELEASE

Karine Lacombe is an infectious diseases specialist whose clinical practice, teaching and research focus on viral infections. Professor Lacombe is head of the infectious diseases department at the Saint-Antoine Hospital, AP-HP, Paris.

She is one of the international leaders on HIV-hepatitis coinfection and has given plenary lectures at all international conferences on infectious diseases. Since March 2020, she has been heavily involved as a clinician and researcher but also at the political level in the management of the Covid-19 crisis.


Her recent publications include Phase 2 and 3 clinical trial results in HIV, chronic hepatitis and SARS-CoV2.

Karine Lacombe graduated from the Pierre and Marie Curie University of Medicine in Paris and completed her internship and clinical training at the Saint-Antoine Hospital in Paris and the Saint-André Hospital in Bordeaux. In 2006, she obtained her PhD in epidemiology on HIV/hepatitis B co-infection and determinants of liver fibrosis. She became an associate professor in infectious diseases in 2007. She has been a full professor at the Sorbonne since 2016.

Catherine George is currently President of Ipsen Innovation and Pharm Sciences, Ipsen's two R&D centers based in France. She is a member of the Board of Directors of France Biotech and a member of the Executive Committee of Medicen.

Catherine George has over 30 years' experience in the pharmaceutical industry and extensive expertise in drug safety through her European and global responsibilities at Pfizer and more recently at Ipsen. Prior to her current position at Ipsen, Catherine George was a member of the R&D management team and responsible for Ipsen's R&D center in Paris Saclay.

Catherine George is a doctor of veterinary medicine with a specialization in veterinary pathology from Cornell University.



DIACCURATE

NEWS RELEASE

DIACCURATE

Diaccurate is exploring the new frontiers of oncology and immunology to identify and develop new therapies with novel mechanisms of action. Currently in clinical phase, the French biotechnology company is leading the development of three proprietary "sole-in-class" drug candidates:

- The company's flagship program is a dual targeted therapy capable of reaching brain metastases: the S6K and AKT1/3 inhibitor (DIACC3010);
- The first targeted chemotherapy: KIF20A inhibitor developed as a small molecule in acute myeloid leukemia (DIACC2010) or as a drug conjugate (DIACC2020) in solid tumors;
- The first CD4 immunotherapy: the anti-PLA2G1B antibody (DIACC1010).

Co-founded by Truffle Capital, the Company has forged alliances with leaders in academia and industry, including Institut Pasteur, Institut Paoli-Calmettes and Merck KAaG. The Company is supported by a first-class management team led by Dominique Bridon and a world-class Scientific Advisory Board chaired by Prof. Tasuku Honjo, 2018 Nobel Prize in Medicine.


For more information, visit www.diaccurate.com and follow [@DiaccurateTx](https://twitter.com/DiaccurateTx)

TRUFFLE CAPITAL

Created in 2001, Truffle Capital is an independent European Venture Capital company, specialising in life sciences (MedTech and Biotech) and in breakthrough IT technologies (FinTech and InsurTech). The mission of Truffle Capital is to help the creation and development of young innovating companies, capable of becoming tomorrow's leaders.

Chaired by Patrick Kron and led by Dr. Philippe Pouletty et Bernard-Louis Roques, co-founders and CEOs, Truffle Capital has raised over €1.1 billion since its inception and helped over 70 companies in the life sciences and digital technology sectors. In 2019, Truffle Capital announced having raised almost €400 million in new institutional funds, including €250 million for new BioMedTech investments.

For more information, visit www.truffle.com and follow [@trufflecapital](https://twitter.com/trufflecapital)



DIACCURATE

NEWS RELEASE

Contacts

DIACCURATE

Dominique Bridon, CEO

33 (0)1 78 95 80 17

contact@diaccurate.com

MC Services AG (ROW)

Anne Hennecke

+49 211 529252 22

Simone Neeten

+49-211-52925217

diaccurate@mc-services.eu

ATCG PARTNERS (France)

Marie Puvieux

+33 (0)9 52 78 85 08

diaccurate@atcg-partners.com

TRUFFLE CAPITAL

DGM CONSEIL

+33 1 40 70 11 89

Thomas de Climens

Quentin Hua

Olivier Labesse

thomasdeclimens@dgm-conseil.fr